Abstract: Systems and methods for hardware accelerated presentation of web pages on mobile computing devices are presented. A plurality of web pages may be received by a computing device capable of processing and displaying web pages using layout engines, hardware accelerated graphics application programming interfaces (APIs). Upon receipt of the web pages, the web pages may be divided into a plurality of rendering layers, based upon stylesheets of the web pages. An algorithm walks through rendering layers so as to select a plurality of layers that may receive compositing layers so as to take advantage of hardware acceleration when rendered. The web pages may be subsequently presented on a display of the mobile computing devices using remaining rendering layers and compositing layers. In this manner, visual representation of web content remains intact even when content which may not have been originally designed for use with layout engine may be displayed.

Abstract: The present invention provides substituted benzimidazole compounds of Formula I: wherein the variables R1, R2, W1, W2, W3, W4, W5, W6, Wa, Wb, Wc and Wd are defined herein. The compounds are useful as phosphoinositide 3-kinase (PI3 kinase) inhibitors.

Abstract: Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.

Abstract: Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.

Abstract: Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.

Abstract: Some embodiments relate to providing an improved progress indicator in a graphical user interface. In addition to conveying a completion status of a task to a user, an improved progress indicator in some embodiments can convey additional information about the task to the user. For example, some embodiments can display a visual cue when a triviality threshold indicating that the task is “substantially complete” is met.

Abstract: The present invention provides substituted benzoxazole compounds of the Formula: wherein the variables R1, R2, W1, W2, W3, W4, W5, are W6 are defined herein. The compounds are useful as phosphoinositide 3-kinase (PI3 kinase) inhibitors.

Abstract: A method of inhibiting phosphatidyl inositol-3 kinase (PI3 kinase), comprising: contacting the PI3 kinase with an effective amount of a compound or pharmaceutically acceptable salt of the formula below, wherein the variables R1, R2, W1, W2, W3, W4, W5, are W6 are defined herein.

Abstract: Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.

Abstract: Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.

Abstract: Some embodiments relate to providing an improved progress indicator in a graphical user interface. In addition to conveying a completion status of a task to a user, an improved progress indicator in some embodiments can convey additional information about the task to the user. For example, some embodiments can display a visual cue when a triviality threshold indicating that the task is “substantially complete” is met.

Abstract: The invention provides in part, conjugate compounds. The invention also provides synthesis methods for making the compounds, and uses of the compounds.

Abstract: The invention provides in part dialkoxybenzene compounds for controlling infestation by a Trichoplusia ni, and methods thereof. The compounds include a compound of Formula I: where R1 may be methyl, ethyl, propyl, n-butyl, isopentyl (3-methylbutyl) or allyl; R2 may be at positions 2, 3 or 4 and may be H, methyl, ethyl, propyl, n-butyl, isopentyl (3-methylbutyl) or allyl; and R3 may be optionally present at positions 2, 3 and 4, and is allyl; except that when R2 is at position 2, R3 if present is at position 3, and when R2 is at position 3, R3 if present is at to positions 2 or 4, and when R2 is at position 4, R3 if present is at position 2, and when R2 is at position 4 and R3, if present, has reacted with an OH group at position 1 in a Markovnikov sense, then R3 becomes R4, a dihydrofuran.

Abstract: Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.

Abstract: Embodiments of the present invention provide a way to perform transforms and animations using Cascading Style Sheets (CSS). CSS may be used to define colors, fonts, layout, and other aspects of document presentation, such as for a webpage. Embodiments of the present invention provide CSS properties for transforms and animations of document content. New CSS properties for transforms allow for rotation, translation, scaling, skewing, perspective, origin, and the like. CSS properties are also provided for animating document content, such as movement, transitions, and the like.

Abstract: The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a PDE4 mediated disease state.

Abstract: The invention provides certain thiazolopyrimidine compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

Abstract: The present invention provides a compound of a formula (I), wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a PDE4 mediated disease state.

Abstract: The invention provides certain thiazolopyrimidine compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

Abstract: The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a PDE 4 mediated disease state.